Is the targeted drug platinib the best choice for RET fusion lung cancer? Analysis of efficacy and adaptability to crowds

Pralsetinib is a targeted drug that specifically targets RET fusion gene mutations and is widely used to treat RET-positive non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. Since the incidence of RET fusion mutations in NSCLC is low, accounting for only about 1%-2%, traditional chemotherapy and immunotherapy are not ideal for these patients.

Platinib, as a highly selectiveRET inhibitor, has demonstrated significant anti-cancer effects in clinical trials, making it an important treatment option for this special patient group. Research data shows that the objective response rate (ORR) of platinib in untreated RET fusion-positive NSCLC patients can reach more than 70%, and in patients who have received platinum chemotherapy, the response rate is also about 60%, showing strong anti-tumor activity.

The therapeutic effects of platinib usually begin to appear within 2-4 weeks after treatmentSome patients can even observe tumor shrinkage within a short period of time, and clinical symptoms such as cough, shortness of breath, chest tightness, etc. are gradually relieved. Compared with traditional treatment methods, platinib can not only significantly delay disease progression, but also improve patients' quality of life. However, this drug is not suitable for all patients with lung cancer. Only patients confirmed by genetic testing to carry RET fusion mutations are suitable for use. Therefore, after diagnosis of non-small cell lung cancer, it is recommended to conduct genetic testing as soon as possible to determine whether the patient is eligible for targeted therapy.

Although platinib has outstanding efficacy in RET fusion-positive lung cancer, it also has certain side effects, such as hypertension, abnormal liver function, anemia, fatigue, etc., and some patients may develop more severe pneumonia-like symptoms. Therefore, blood pressure, liver and kidney function need to be closely monitored during medication, and the dose needs to be adjusted according to the patient's tolerance. For patients with RET fusion mutations, platinib is undoubtedly one of the best targeted treatment options currently. However, a reasonable treatment plan still needs to be developed under the guidance of a doctor based on individual circumstances to ensure maximum efficacy and reduce the risk of side effects.

Reference materials:https://gavreto.com/